Rubicon and Avantor team on excipient development

- Last updated on GMT

Rubicon and Avantor to develop drug excipients
Rubicon Research and Avantor have teamed up to develop a gastro-retentive excipient for pharmaceutical applications.

Specific details of the project have not been disclosed, although the general idea is to combine Mumbai, India-based Rubicon’s delivery technology with Avantor’s manufacturing and marketing capacity. The firms plan to launch the product next year.

Rubicon CEO Pratibha Pilgaonkar said: “This material will provide solutions to the global pharmaceutical industry for molecules with challenging therapeutic requirements, either from the pipelines of innovator companies or for life cycle management opportunities for already marketed products​.”

The firm did not respond to requests for additional information ahead of publication.

Related news

Related products

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers